International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor–Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome

Arthritis Care and Research

Volumn 69, Issue 4, 2017, Pages 578-586

  Ozen, Seza ^a   Kuemmerle Deschner, Jasmin B ^b   Cimaz, Rolando ^c   Livneh, Avi ^d   Quartier, Pierre ^e   Kone Paut, Isabelle ^f   Zeft, Andrew ^g   Spalding, Steve ^h   Gul, Ahmet ⁱ   Hentgen, Veronique ^j   Savic, Sinisa ^k   Foeldvari, Ivan ^l   Frenkel, Joost ^m   Cantarini, Luca ⁿ   Patel, Dony ^o   Weiss, Jeffrey ^o   Marinsek, Nina ^o   Degun, Ravi ^o   Lomax, Kathleen G ^p   Lachmann, Helen J ^q  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Phoenix Children's Hospital   (France)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

^j BICÊTRE HOSPITAL   (France)

^k LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^l Hamburger Zentrum fur Kinder und Jugendrheumatologie   (Germany)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ UNIVERSITY OF SIENA   (Italy)

^o Navigant Consulting Inc   (United Kingdom)

^p Novartis Pharma   (France)

^q UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANAKINRA; CANAKINUMAB; ETANERCEPT; MEVALONATE KINASE; PYRIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; DELAYED DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG CHOICE; DRUG RESPONSE; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFANT; INFLAMMATION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEFV GENE; MEVALONATE KINASE DEFICIENCY; MVK GENE; ONSET AGE; PATIENT REFERRAL; TERTIARY CARE CENTER; TNFRSF1A GENE; TREATMENT DURATION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UNSPECIFIED SIDE EFFECT; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; ELECTRONIC HEALTH RECORD; EUROPE; FEMALE; GENETICS; HEREDITARY AUTOINFLAMMATORY DISEASES; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; DELAYED DIAGNOSIS; ELECTRONIC HEALTH RECORDS; EUROPE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; FEVER; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFANT; MALE; MEVALONATE KINASE DEFICIENCY; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85014314541     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23120     Document Type: Article

References (22)

1. Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 2009;120:413–8.
2. Ozen S, Y. Bilginer. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2014;10:135–47.
3. Yao Q, Furst DE. Autoinflammatory diseases: an update of clinical and genetic aspects. Rheumatology (Oxford) 2008;47:946–51.
4. Schmaltz R, Vogt T, Reichrath J. Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2010;2:26–9.
5. Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014;73:2160–7.
6. Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636–44.
7. Caminero A, Comabella M, Montalban V. Role of tumour necrosis factor (TNF)-alpha and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. Clin Exp Immunol 2011;166:338–45.
8. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998;351:659–64.
9. Cetin GY, Balkarli A, Oksuz AN, Kimyon G, Pehlivan Y, Orhan O, et al. Evaluation of frequency and the attacks features of patients with colchicine resistance in FMF. Rev Bras Reumatol 2014;54:356–9. In Portuguese.
10. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012;157:533–41.
11. Hashkes PJ, Spalding SJ, Hajj-Ali R, Giannini EH, Johnson A, Barron KS, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int 2014;2014:854842.
12. Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study [letter]. Arthritis Rheumatol 2014;66:3241–3.
13. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 2013;43:387–91.
14. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016;75:644–51.
15. Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009;61:1447–53.
16. Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001;9:553–5.
17. Ben-Chetrit E, Ben-Chetrit E. The rise and fall of FMF research: fifty years of publications. Clin Exp Rheumatol 2005;234 Suppl 38:S3–7.
18. Dandekar P, Gregson J, Campbell R, Bianic F. Living with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS). Ped Rheumatol 2015;13 Suppl 1:P23.
19. Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72:678–85.
20. Long SS, Pickering LK, Prober CG. Principles and practice of pediatric infectious diseases. Philadelphia; Saunders: 2012.
21. Cerrito L, Sicignano LL, Verrecchia E, Manna R. Epidemiology of FMF worldwide. In: M. Gattorno, editor. Familial Mediterranean fever (rare diseases of the immune system). New York: Springer International Publishing; 2015. p. 81–90.
22. Bodar EJ, Kuijik LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 2011;70:2155–8.